Azenta 8K Results of Operations and Financial Condition | AZTA 9 Feb 12

Exhibit 99.2

LOGO

Exhibit 99.2

1st Quarter Fiscal 2012 Financial Results Conference Call

February 9, 2012

LOGO

Safe Harbor Statement

“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. Further discussions of risk factors are available in the Company’s most recent SEC filings including form 10-K for the fiscal year ended 9/30/11. The Company assumes no obligation to update the information in this presentation.

Regulation G

This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Brooks business and it’s operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant GAAP amount are provided in either an attachment to our first quarter financial results press release issued on February 9, 2012 or as an attachment to call slides used to accompany prepared comments made during our financial results conference call of the same date. Both documents are available on our web site at www.brooks.com.

LOGO

Significant Events in the December Quarter

Full quarter of Nexus BioSystems acquisition compared to 2 months reflected in September quarter

Balance sheet includes Celigo product line acquisition that closed on December 30, 2011

Significant slow down in Semiconductor activity early in the quarter with a strong rebound in the last few weeks of the quarter

Industrial capital spend reductions with largest declines for Polycold mixed gas cryo chillers

Effective tax rate fluctuating from quarter to quarter

LOGO

Revenue and Operating Profits Waterfall

Revenues Operating Profit

$ millions before Special Charges

4th Quarter Fiscal 2011 $ 131.0 $ 9.7

Brooks Life Science Systems 4.3 1.6

Brooks Product Solutions ( 13.2) ( 7.4)

Brooks Global Services ( 1.8) ( 1.3)

Amortization increase in SG&A ( 0.2)

1st Quarter Fiscal 2012 $ 120.2 $ 2.3

LOGO

Fixed Cost Absorption and Mix Impact Margins

$ millions Q4FY11 Q1FY12 Change

Revenues $ 131.0 $ 120.2 $ ( 10.8)

Gross Profit, (excluding acquisition accounting)* 48.6 40.7 (7.9)

Gross Margin % 37.1% 33.9%—3.2%

Research & development 11.5 11.9 (0.4)

Selling, general & administrative 27.4 26.5 0.9

Operating Income (before special charges)* $ 9.7 $ 2.3 $ (7.4)

* Non –GAAP measure See www.brooks.com for reconciliation to the appropriate GAAP measure

LOGO

Income Taxes impact Special Charges

$ millions Q4FY11 Q1FY12 Change

Revenues $ 131.0 $ 120.2 $ ( 10.8)

Operating profit (before special charges)* 9.7 2.3 ( 7.4)

Special charges* 0.0 ( 0.8) ( 0.8)

Other items 0.7 0.6 ( 0.1)

Income tax benefit (provision), 0.6 ( 0.3) ( 0.9)

excluding non-recurring items*

Minorities & joint venture earnings 1.1 1.2 0.1

Net Income Attributable to Brooks $ 12.1 $ 3.0 $ (9.1)

GAAP DEPS $ 0.19 $ 0.05 $(0.14)

Adjusted DEPS * $ 0.19 $ 0.06 $(0.13)

* Non –GAAP measure See www.brooks.com for reconciliation to the appropriate GAAP measure

LOGO

Cash and Cash flow

$ millions FY12 Q1

Adjusted EBITDA * $ 10.8

Working Capital movements (4.3)

Restructuring & undistributed joint venture earnings ( 1.4)

Cash Flow from Operations 5.1 Capital expenditures ( 2.1) Dividends ( 5.2) Celigo acquisition ( 8.7) Other ( 0.4)

Net Change in Cash and Marketable securities ( 11.3)

Cash and Marketable securities at December 31 $ 194.5

* Non –GAAP measure See www.brooks.com for reconciliation to the appropriate GAAP measure

LOGO

Diversification and Dilution of Customer Exposures

FY11 Q1 FY12 Q1

# of >10% Customers 2 1

% of Business to Top

47% 25%

3 Customers

9% 11%

11% 51%

18%

FY12Q1

Semi front end products

BGS

Industrial

Life Sciences

Other adjacencies

LOGO

Brooks Life Science Systems

Reconciliation of GAAP to underlying performance

Q1FY12 Adjust- Q1FY12

$ millions Comments

GAAP ments Non-GAAP

Adjustment for fair value

Revenues $ 12.8 $ 0.5 $ 13.3 accounting on contracts

acquired

Gross Profit 4.8 0.4 5.2 39% underlying gross margin

Increased R&D with

Operating 5.5 0.0 5.5 integration savings offsetting

Expenses full quarter effect for SG&A

Segment $( 0.6) $( 0.3)

Operating Loss

LOGO

Brooks Product Solutions Sequential Performance

Comments on

$ millions Q4FY11 Q1FY12

Sequential Trends

Industrial product revenues

Revenues $ 98.5 $ 85.3 down $10 million

Margin of 33.3% impacted by

Gross Profit 36.7 28.4 absorption and mix

Operating Expenses 28.7 27.3

Segment Operating

Income $ 8.0 $ 1.1 1.3% operating margin

LOGO

Brooks Global Services Sequential Performance

Comments on $ millions Q4FY11 Q1FY12 Sequential Trends

Revenues $ 23.9 $ 22.1 Decline in spare part demand

Spares mix and favorable Gross Profit 8.7 7.1 materials cost in Sept quarter

Operating Expenses 4.5 4.2

Segment Operating $ 4.2 $ 2.9 13.3% operating margin Income

LOGO

Revenue, Margin & Earnings Guidance

$ millions Q1FY11 Q2FY12 Comments on Sequential Trends

Front End Semiconductor equipment

recovery. Continued growth in Life

Revenues $ 120.2 $132.0—$140.0 Science Systems business.

$3.5 million reduction in expenses

Adjusted Diluted from recovery of previously expensed

$ 0.06 $ 0.15—$0.20

Earnings Per Share* legal costs and $1.2 million income

tax benefit

$3.0 million in-process R&D charge

GAAP Diluted from IP acquisition. Small

$ 0.05 $ 0.09—$0.14

Earnings Per Share acquisition accounting adjustments

for Life Science Systems

* Non –GAAP measure. See www.brooks.com for reconciliation of historical measure to GAAP measure

LOGO

1st Quarter Fiscal 2012 Financial Results Conference Call

February 9, 2012

LOGO

GAAP to Non-GAAP Reconciliation – Q4 FY11 vs. Q1 FY12

GAAP non-GAAP GAAP non-GAAP

in millions Q4 FY11 Adjust Q4 FY11 Q1 FY12 Adjust Q1 FY12

Revenues $ 131.0 $—$ 131.0 $ 120.2 $—$ 120.2

Cost of revenues 84.0 (1.6) 82.4 79.9 (0.4) 79.5

Gross profit 47.0 1.6 48.6 40.3 0.4 40.7

Operating expense:

Research & development 11.5 —11.5 11.9 —11.9

Selling, general & administrative 28.1 (0.7) 27.4 26.7 (0.2) 26.5

Restructuring 0.5 (0.5)—0.2 (0.2) -

40.1 (1.2) 38.9 38.8 (0.4) 38.4

Operating profit (loss) 6.9 2.8 9.7 1.5 0.8 2.3

Interest income, net 0.3 —0.3 0.3 —0.3

Sale of contract manufacturing business——— —-

Other, net 0.4 —0.4 0.3 —0.3

Income before taxes, joint ventures and minority interest 7.6 2.8 10.4 2.1 0.8 2.9

Income tax provision (3.4) 2.8 (0.6) 0.3 —0.3

Net income before joint ventures and minority interest 11.0 —11.0 1.8 0.8 2.6

Joint venture income (losses) 1.1 —1.1 1.2 —1.2

Net income 12.1 —12.1 3.0 0.8 3.8

Net (income) loss attributable to minority interests (0.0) —(0.0) (0.0) —(0.0)

Net income (loss) attributable to Brooks $ 12.1 $—$ 12.1 $ 3.0 $ 0.8 $ 3.8

Basic earnings per share attributable to Brooks $ 0.19 $—$ 0.19 $ 0.05 $ 0.01 $ 0.06

Diluted earnings per share attributable to Brooks $ 0.19 $—$ 0.19 $ 0.05 $ 0.01 $ 0.06

Basic shares for EPS 64,750 64,750 64,750 64,812 64,812 64,812

Diluted shares for EPS 65,118 65,118 65,118 65,309 65,309 65,309

Adjustments

Cost of revenues

Purchasing accounting adjustments to sales contracts $ (1.0) $ (0.4)

Inventory charges recorded for acquisitions (0.6) —

$ (1.6) $ (0.4)

Operating expense:

Merger costs $ (0.7) $ (0.2)

Restructuring (0.5) (0.2)

$ (1.2) $ (0.4)

Income tax provision

One-time benefit from uncertain tax positions $ 2.8 $—

Azenta (AZTA) 8-KResults of Operations and Financial Condition